Skip to main content

Advertisement

SpringerLink
Log in

The clinicopathological characteristics with long-term outcomes in malignant mesothelioma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Malignant mesothelioma (MM) is a neoplasm which originates from serous membranes. It is relatively more common in Turkey. Ninety-nine patients between 2002–2009 were evaluated for survival and patient characteristics with chest pain, dyspnea, weight loss, loss of appetite, anemia, leukocytosis, thrombocytosis and lactate dehydrogenase (LDH) elevation, retrospectively. Male/female ratio was 1.41(58/41). Median age was 53(27–88). Asbestosis exposure rate was 78.5 %. Most of the patients had better ECOG-PS (88.7 % for 1–2). Chest pain (47.7 %), dyspnea (44.8 %), weight loss (49 %), loss of appetite (50 %), anemia (38 %), leukocytosis (37.2 %), thrombocytosis (26.6 %) and LDH elevation (10.1 %) were found with median values such as 11.8 g/dL (5–17.1) for hemoglobin, 8,800/mm3 for WBC (2,600–38,300), 382,000/mm3 for platelets (28,000–1,504,000) and 253 IU/L for LDH (85–1,877), respectively. The most common site was pleura (62.3 %). Half of the patients were unclassified, while epitheloid histopathology (39.4 %) was most common in classified ones. RT rate was 42.1 % in operated patients and all had pleural MM. Median OS was 22.9 months. Eighty percent of the patients had first-line CT with a clinical benefit rate of 63.3 %. Second-line CT rate was 29 % with a clinical benefit rate of 44 %. Most preferred CT regimen was cisplatinum and pemetrexed. Most of the patients were male in their 50 s with pleural MM. They had chest pain, dyspnea, weight loss and loss of appetite as the most common symptoms at diagnosis. Only half of the patients could be subtyped with a predominance of epitheloid histology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–31.

    Article  PubMed  CAS  Google Scholar 

  2. Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol. 2005;16:345–51.

    Article  PubMed  CAS  Google Scholar 

  3. Emri S, Kocagoz T, Olut A, Güngen Y, Muti L, Baris YI. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. Anticancer Res. 2000;20:891–4.

    PubMed  CAS  Google Scholar 

  4. Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell’Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol. 2000;75:55–8.

    Article  PubMed  CAS  Google Scholar 

  5. Selçuk T, Cöplü L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 1992;102:790–6.

    Article  PubMed  Google Scholar 

  6. Loggie BW. Malignant peritoneal mesothelioma. Curr Treat Options Oncol. 2001;2:395–9.

    Article  PubMed  CAS  Google Scholar 

  7. Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006;66:5063–8.

    Article  PubMed  CAS  Google Scholar 

  8. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin. 2004;14:469–77.

    Article  PubMed  Google Scholar 

  9. Elkiran ET, Kaplan MA, Sevinc A, et al. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol. 2012;29:3147–54.

    Article  PubMed  Google Scholar 

  10. Utkan G, Ürün Y, Cangir AK, et al. Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups. Asian Pac J Cancer Prev. 2013;14:249–53.

    Article  PubMed  Google Scholar 

  11. Kindler HL. Systemic treatments for mesothelioma: Standard and novel. Curr Treat Options Oncol. 2008;9:171–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.

    Article  PubMed  Google Scholar 

  13. Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010;80:480–7.

    Article  PubMed  Google Scholar 

  14. Lee KH, Yoon HS, Choi SJ, et al. Asbestos exposure and malignant mesothelioma in Korea. Asian Pac J Cancer Prev. 2009;10:707–10.

    PubMed  Google Scholar 

  15. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289–95.

    Article  PubMed  Google Scholar 

  16. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003;9:476–84.

    Article  PubMed  Google Scholar 

  17. Stahel RA, Weder W, Lievens Y, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;2010(21):126–8.

    Article  Google Scholar 

  18. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78:92–111.

    Article  PubMed  Google Scholar 

  19. Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:163–72.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Utkan G, Büyükçelik A, Yalçin B, Akbulut H, Demirkazik A, Dinçol D, Onur H, Gören D, Mousa U, Senler FC, Içli F. Divided dose of cisplatinum combined with gemcitabine in malignant mesothelioma. Lung Cancer. 2006;53:367–74.

    Article  PubMed  Google Scholar 

  21. Kindler HL. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000;1:313–26.

    Article  PubMed  CAS  Google Scholar 

  22. van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP. Multicenter phase II study of gemcitabine and cisplatinum in malignant pleural mesothelioma. Br J Cancer. 2002;86:342–5.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW. Cisplatinum and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30.

    PubMed  CAS  Google Scholar 

  24. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicenter phase II study of cisplatinum and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.

    Article  PubMed  CAS  Google Scholar 

  26. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888–96.

    Article  PubMed  Google Scholar 

  27. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatinum followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–13.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451–7.

    Article  PubMed  CAS  Google Scholar 

  29. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res. 2009;29:3441–4.

    PubMed  CAS  Google Scholar 

  30. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.

    Article  PubMed  Google Scholar 

  31. Krug LM, Wozniak AJ, Kindler HL, et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer 2014 Jul 5. doi: 10.1016/j.lungcan.2014.06.008. [Epub ahead of print].

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Ankara Numune Training and Research Hospital, 06100, Altindag, Ankara, Turkey

    Mutlu Dogan, Cemil Hocazade, Dogan Uncu, Serife Toptas, Nuriye Ozdemir & Nurullah Zengin

  2. Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey

    Gungor Utkan & Fikri Icli

Authors
  1. Mutlu Dogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gungor Utkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cemil Hocazade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dogan Uncu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Serife Toptas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nuriye Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nurullah Zengin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fikri Icli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mutlu Dogan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dogan, M., Utkan, G., Hocazade, C. et al. The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. Med Oncol 31, 232 (2014). https://doi.org/10.1007/s12032-014-0232-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0232-0

Keywords

Search

Navigation